NCT06267846CompletedPhase 2
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- First submitted
- 12 Feb 2024
- Start date
- 20 Mar 2024
- Primary completion date
- 25 Jul 2025
- Lead sponsor
- Neurocrine Biosciences
- Diseases
- Depression
- NCT number
- NCT06267846
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 73
- From 20 Mar 2024 to the primary completion date, 25 Jul 2025
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than MDD.
- Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy.
Other illness
- Participant has an unstable medical condition or unstable chronic disease.
- Participant has a history of neurological abnormalities.
- Participant has an alcohol or substance use disorder.
- Note: Other inclusion/exclusion criteria may apply
Other
- Participants will be excluded from the study if they meet any of the following criteria:
- Participant is pregnant or breastfeeding or plan to become pregnant during the study.
Who the study is looking for
- Participants must meet all of the following inclusion criteria:
- Primary diagnosis of recurrent MDD or persistent MDD.
- Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening and must be willing and able to continue with current antidepressant medication(s).
- Participants must be willing and able to comply with all study procedures and restrictions.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Save your city in your profile to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.